

Beyond Inhibition. Reprogramming Cancer Control.

Kazia Therapeutics Limited (“Kazia”) is a Sydney-based clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet need.

Financial Insights

Cash & Cash Equivalents:

~ US\$46 million

(Runway expected to fund planned operations into 2029, excluding additional or expanded trials)

Debt:

No outstanding debt

Ticker: KZIA (NASDAQ)

American Depositary Shares

Outstanding:

~ 11.4 million



Key Investment Highlights

Portfolio:

- **Paxalisib**, a brain-penetrant, oral, small molecule dual PI3K / mTOR inhibitor with epigenetic and immunomodulatory activity
- PD-L1 protein degrader platform lead compound, **NDL2**, an optimized bicyclic peptide PD-L1 degrader designed to target intracellular PD-L1, thereby restoring anti-tumor immune responses even in cases of immune evasion or checkpoint inhibitor resistance
- SETDB1 inhibitor platform lead compound, **MSETC**, an optimized, bicyclic peptide designed to target SETDB1, a key epigenetic regulator of immune evasion
- **EVT801**, a small molecule selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor


Partnerships and Collaborations: Genentech (paxalisib global license), Simcere (paxalisib Greater China), QIMR Berghofer (exclusive research collaboration and in-licensing), Evotec SE (EVT801 global license), Sovargen (paxalisib select neurology), Pacific Pediatric Neuro-Oncology Consortium, Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, and Dana-Farber Cancer Institute.

Proven Leadership: Dr. John Friend (CEO), Dr. Sudha Rao (CSO), and Jeffrey Kraws (Head Corporate Strategy & Development) bring clinical, operational, and market expertise to support current and future phases of development.

Milestones & Anticipated Catalysts

- Q4 2025** Pricing of \$50 million private placement of equity securities
- Q1 2026** Clinical trial update; Complete metabolic response in stage IV TNBC expanded access patient and 2 partial responses in metastatic TNBC Phase 1b study
- Q1 2026** PD-L1 protein degrader (NDL2) preclinical and translational data update
- Q2 2026** In-licensing of SETDB1 inhibitor platform
- Q2 2026** Appointment of Dr. Sudha Rao as Chief Scientific Officer
- Q2 2026** Update from FDA discussion regarding paxalisib commercial and development path forward in GBM
- Q2 2026** Advancement of NDL2 and MSETC towards IND-enabling studies
- 2H 2026** Readouts from neuro-oncology focused clinical trials in patients with GBM and brain metastases
- 2H 2026** Clinical efficacy and biomarker data from ongoing Phase 1b breast cancer study
- 2H 2026** Provide update of paxalisib pre-clinical development into additional breast cancer subtypes
- 2H 2026** Publication/Presentation of translational data supporting therapeutic reprogramming strategy for paxalisib

Pipeline Snapshot



*product candidate (not approved)